A securities class action has been filed in the USDC — E.D.PA. against Ocugen, Inc. (OCGN) (“Ocugen” or the “Company”), On behalf of all persons or entities who purchased or otherwise acquired Ocugen securities publicly traded on the NASDAQ between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”).

Defendant Ocugen is a biotechnology company.

The complaint alleges, Defendants made false and/or misleading statements and/or failed to disclose that:

(1) Ocugen’s financial statements from May 8, 2020 to the present were materially misstated;

(2) Ocugen did not have adequate internal controls; and

(3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times, thereby harming investors.

If you purchased Ocugen securities during the class period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.